Pleiotropic effects of the non-calcium phosphate binder sevelamer I.G. Nikolov, N. Joki, J. Maizel, B. Lacour, T.B. Drüeke, Z.A. Massy  Kidney International  Volume 70, Pages S16-S23 (December 2006) DOI: 10.1038/sj.ki.5001994 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan–Meier estimates for all-cause mortality (upper panel) and CV mortality (lower panel) in hemodialysis patients according to baseline hs-CRP quartile. (Reproduced with permission from Wanner et al. Kidney Int 2003). Kidney International 2006 70, S16-S23DOI: (10.1038/sj.ki.5001994) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 Possible causes of inflammatory cascade activation in uremia and dialysis. (Reproduced with permission from Wanner and Metzger, Nephrol Dial Transplant 2002). Kidney International 2006 70, S16-S23DOI: (10.1038/sj.ki.5001994) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 Mean change in serum uric acid concentrations over 52 weeks by baseline concentration. (Reproduced with permission from Garg et al. Arth Rheum 2005). Kidney International 2006 70, S16-S23DOI: (10.1038/sj.ki.5001994) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 4 A side-by-side comparison of change in mean trabecular bone attenuation and change in mean coronary artery calcification (Agatston) score in subjects randomized to calcium and sevelamer. (Reproduced with permission from Raggi et al. J Bone Miner Res 2005). Kidney International 2006 70, S16-S23DOI: (10.1038/sj.ki.5001994) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 5 Potential pleiotropic effects of sevelamer in CKD. Kidney International 2006 70, S16-S23DOI: (10.1038/sj.ki.5001994) Copyright © 2006 International Society of Nephrology Terms and Conditions